open access

Vol 64, No 3 (2006)
Other
Published online: 2006-03-29
Submitted: 2012-12-28
Get Citation

ORGINAL ARTICLE
Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure

Piotr Kübler, Jolanta Petruk-Kowalczyk, Jacek Majda, Krzysztof Reczuch, Waldemar Banasiak, Piotr Ponikowski
Kardiol Pol 2006;64(3):250-256.

open access

Vol 64, No 3 (2006)
Other
Published online: 2006-03-29
Submitted: 2012-12-28

Abstract

Introduction: Monitoring of natriuretic peptide concentration may be useful for the identification of high-risk patients presenting with decompensated chronic heart failure (CHF). Aim: Assessment of the predicting value of a significant decrease (by ≥20% vs. baseline) of N-terminal proBNP (NTpro-BNP, ROCHE) concentration during hospitalisation in patients with decompensated CHF. Methods: This study involved 54 patients admitted to our centre because of CHF decompensation. Concentration of NTpro-BNP was measured on admission and at discharge from hospital. Primary end-points of this study were overall mortality and mortality with a number of cardiovascular-related readmissions. Results: Mean NTpro-BNP concentration on admission was 7435±10040 pg/ml and at the time of discharge from hospital – 4816±7822 pg/ml. In 31 (57%) patients a significant decrease (≥20% vs baseline value) in NTpro-BNP level (mean: –58%±21%) was noted, while in the remainder (23 patients; 43%) neither an increase nor a decrease in NTpro-BNP levels was observed (mean: +72%±132%) despite optimal treatment and stabilisation of the clinical status. The mean follow-up duration was 358±240 days. Cox analysis showed that the absence of significant NTpro-BNP level decrease was associated with an increased risk of death – RR: 3.69 (95% CI: 1.10–12.37; p=0.035) and was the single independent risk factor for readmission due to cardiovascular-related reasons and/or death – RR: 2.29 (95% CI: 1.20–4.35; p=0.01). In the group of 23 patients with an increase or decrease in NTpro-BNP concentration of more than or equal to 20%, the survival rate was 65% vs. 87% in the remainder (p=0.02). Conclusions: The lack of a significant (≥20%) decrease of NTpro-BNP level during hospitalisation correlates with a higher mortality and rate of readmissions. NTpro-BNP level monitoring may be of clinical importance for risk stratification in patients hospitalised for decompensated CHF.

Abstract

Introduction: Monitoring of natriuretic peptide concentration may be useful for the identification of high-risk patients presenting with decompensated chronic heart failure (CHF). Aim: Assessment of the predicting value of a significant decrease (by ≥20% vs. baseline) of N-terminal proBNP (NTpro-BNP, ROCHE) concentration during hospitalisation in patients with decompensated CHF. Methods: This study involved 54 patients admitted to our centre because of CHF decompensation. Concentration of NTpro-BNP was measured on admission and at discharge from hospital. Primary end-points of this study were overall mortality and mortality with a number of cardiovascular-related readmissions. Results: Mean NTpro-BNP concentration on admission was 7435±10040 pg/ml and at the time of discharge from hospital – 4816±7822 pg/ml. In 31 (57%) patients a significant decrease (≥20% vs baseline value) in NTpro-BNP level (mean: –58%±21%) was noted, while in the remainder (23 patients; 43%) neither an increase nor a decrease in NTpro-BNP levels was observed (mean: +72%±132%) despite optimal treatment and stabilisation of the clinical status. The mean follow-up duration was 358±240 days. Cox analysis showed that the absence of significant NTpro-BNP level decrease was associated with an increased risk of death – RR: 3.69 (95% CI: 1.10–12.37; p=0.035) and was the single independent risk factor for readmission due to cardiovascular-related reasons and/or death – RR: 2.29 (95% CI: 1.20–4.35; p=0.01). In the group of 23 patients with an increase or decrease in NTpro-BNP concentration of more than or equal to 20%, the survival rate was 65% vs. 87% in the remainder (p=0.02). Conclusions: The lack of a significant (≥20%) decrease of NTpro-BNP level during hospitalisation correlates with a higher mortality and rate of readmissions. NTpro-BNP level monitoring may be of clinical importance for risk stratification in patients hospitalised for decompensated CHF.
Get Citation

Keywords

congestive heart failure; brain natriuretic peptide; prognosis

About this article
Title

ORGINAL ARTICLE
Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 64, No 3 (2006)

Pages

250-256

Published online

2006-03-29

Bibliographic record

Kardiol Pol 2006;64(3):250-256.

Keywords

congestive heart failure
brain natriuretic peptide
prognosis

Authors

Piotr Kübler
Jolanta Petruk-Kowalczyk
Jacek Majda
Krzysztof Reczuch
Waldemar Banasiak
Piotr Ponikowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl